Arrowhead Pharmaceuticals Return on Equity

Arrowhead Pharmaceuticals (ARWR) currently reports a ROE of -50.24%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore Arrowhead Pharmaceuticals's ROE history and peer comparisons.

Arrowhead Pharmaceuticals's ROE of -50.24% is lower than the Healthcare sector average of 29.33%. That is roughly 271.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Arrowhead Pharmaceuticals's current -50.24% should be judged against Healthcare norms (sector average: 29.33%) and against ARWR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -50.24%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Arrowhead Pharmaceuticals, and consider following ARWR for alerts when major investors trade the stock.

Arrowhead Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -50.24% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ARWR with unrelated industries.